 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 07/09/2003 | | | | Nymox Recommended in Three Recent Independent Analyst Reports
topic: Financial
July 9, 2003: Three current independent analyst reports recommend Nymox Pharmaceutical Corporation. The most recent "Buy" recommendation is from Dutton and Company, written by Sherry Grisewood, CFA on June 26, 2003. The "Speculative Buy" from WallStreet Research was written by Alan Stone on June 19, 2003. The "Buy" recommendation from Kareg Corporation was written by Sheldon S. Traube, Director of Research on June 16, 2003. |
| 07/08/2003 | | | | Statin Drugs and Their Promise Against Alzheimer's Disease Featured in Cover Story of Newsweek Magazine
topic: Statins and Alzheimer's Disease
July 8, 2003: The July 14 issue of Newsweek magazine features a cover story on statin drugs and how they now show promise against Alzheimer's disease and other indications. Nymox Pharmaceutical Corporation holds a U.S. patent and global rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. |
| 07/03/2003 | | | | Employee Benefit Programs in U.S. Increase Coverage of Smoking Cessation Programs
topic: Tobacco Exposure Tests
July 3, 2003: Coverage for smoking cessation programs is part of comprehensive cancer screening and prevention programs agreed to by the CEOs of several dozen major corporations. The programs will extend the benefit of smoking cessation programs to 8 million employees and 17 million dependents. Smoking cessation programs have been traditionally excluded from such employee benefit programs. |
| 07/02/2003 | | | | Beef Recall Highlights Need for E. Coli Treatment
topic: R&D: E coli and Other Antibacterial Treatments
July 2, 2003: The recent recall of approximately 739,000 pounds of frozen beef, mostly vacuum packaged steaks, dramatically demonstrates the need for an effective treatment of contamination of food and drink products by potentially deadly E. coli O157:H7 bacteria according to Dr. Michael Munzar, Medical Director of Nymox Pharmaceutical Corporation. |
| 06/30/2003 | | | | Nymox Products Widely Featured on U.S. Television
topic: Marketing
June 30, 2003: Nymox Pharmaceutical Corporation products have been extensively featured in U.S. television broadcasts throughout the month of June. News of the Company's NicAlert™ and AlzheimAlert™ products and parts of the Company's R&D pipeline reached an audience of an estimated 10 to 15 million television viewers in the U.S. |
| 06/27/2003 | | | | Dutton & Associates Reiterate "Buy" Recommendation for Nymox Pharmaceutical Corporation
topic: Financial
June 27, 2003: Nymox Pharmaceutical Corporation announced today that J M Dutton & Associates have reiterated a "buy" recommendation for Nymox in a new Research Note. |
| 06/26/2003 | | | | Alzheimer's Disease Highlighted as Potential New Indication for Statin Drugs
topic: Statins and Alzheimer's Disease
June 26, 2003: Statin drugs for lowering cholesterol may have unexpected preventive and treatment benefits for several new indications according to recent studies. The potential benefits of statin drug use in the treatment or prevention of Alzheimer's disease was highlighted in a recent feature article in The Los Angeles Times on June 22, 2003. |
| 06/25/2003 | | | | American Respiratory Alliance Will Use Nymox's NicAlert™ as its Official Test Agent in Smoking Cessation Programs
topic: Tobacco Exposure Tests
June 25, 2003: Nymox Pharmaceutical Corporation and the American Respiratory Alliance jointly announced today that NicAlert™ will be used as the official test agent in several smoking cessation programs to be offered by the American Respiratory Alliance. |
| 06/24/2003 | | | | Nymox Pharmaceutical Corporation Recommended in Three Current Independent Analyst Reports
topic: Financial
June 24, 2003: Three recent independent analyst reports have recommended Nymox Pharmaceutical Corporation (NASDAQ: NYMX). The "Speculative Buy" from WallStreet Research was written by Alan Stone on June 19, 2003. The "Buy" recommendation from Kareg Corporation was written by Sheldon S. Traube, Director of Research on June 16, 2003. The "Buy" recommendation from Dutton and Company was written by Sherry Grisewood, CFA on May 15, 2003. |
| 06/20/2003 | | | | Nymox Rated "Speculative Buy" By New WallStreet Research Report
topic: Financial
June 20, 2003: Nymox Pharmaceutical Corporation shares were given a "speculative buy" recommendation in a new report issued today by WallStreet Research. |
|